| Name | Title | Contact Details |
|---|
DiagnoCure (TSX: CUR; OTCQX: DGCRF) is a life sciences corporation that develops and commercializes high-value cancer diagnostic tests that increase clinician and patient confidence in making critical treatment decisions. In 2008, the Corporation launched a colorectal cancer staging test through its U.S. CLIA laboratory. PrevistageTM GCC is currently available for licensing. The Corporation has granted a worldwide exclusive license on the diagnostic applications of its proprietary molecular biomarker PCA3 to Gen-Probe, now a wholly-owned subsidiary of Hologic Inc. Hologic Gen-Probe's PROGENSA® PCA3 prostate cancer test is commercialized in Europe under CE mark and is approved for commercialization in Canada and the United States.
A machine built to move with you. CLMBR offers a unique combination of high intensity cardio, resistance strength training, and connected technology.
Neotonus Inc is a Marietta, GA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Renowned for compassionate care, St. Joseph`s Health Care London is one of the best academic health care organizations in Canada dedicated to helping people live to their fullest by minimizing the effects of injury, disease and disability through excellence in care, teaching and research. St. Joseph`s is a Catholic health care organization, owned by the St. Joseph`s Health Care Society of the Roman Catholic Diocese of London and governed by a volunteer board of directors representing the community. Our services are publicly funded. We are a partner in London`s academic health sciences community.
FibroGen is a research-based biotechnology company using its expertise in connective tissue growth factor (CTGF) and hypoxia-inducible factor (HIF) biology to discover, develop, and commercialize novel therapeutics for serious unmet medical needs. FibroGen’s research team is committed to discovering novel therapies in areas of major unmet medical need. Our goal is to continue to provide pipeline candidates supported by rigorous data in well-characterized therapeutic settings. All of FibroGen`s therapeutic candidates have been internally developed based on FibroGen`s pioneering research in two important areas of biology, hypoxia-inducible factor (HIF) and connective tissue growth factor (CTGF).